Home » Stocks » Cassava Sciences

Cassava Sciences, Inc. (SAVA)

Stock Price: $2.95 USD -0.01 (-0.34%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.05 +0.10 (3.39%) Aug 7, 7:57 PM

Stock Price Chart

Key Info

Market Cap 73.10M
Revenue (ttm) n/a
Net Income (ttm) -4.42M
Shares Out 24.78M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE 45.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $2.95
Previous Close $2.96
Change ($) -0.01
Change (%) -0.34%
Day's Open 2.96
Day's Range 2.87 - 3.01
Day's Volume 596,757
52-Week Range 1.03 - 10.95

More Stats

Market Cap 73.10M
Enterprise Value 47.57M
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.78M
Float 22.12M
EPS (basic) -0.24
EPS (diluted) -0.23
FCF / Share -0.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.39M
Short Ratio 1.41
Short % of Float 15.25%
Beta 2.99
PE Ratio n/a
Forward PE 45.25
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.11
Revenue n/a
Operating Income -4.73M
Net Income -4.42M
Free Cash Flow -3.00M
Net Cash 25.53M
Net Cash / Share 1.03
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -13.27%
ROE -20.39%
ROIC 753.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $2.95
Target: 16.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth------277.58%-5.17%-31.68%-
Gross Profit------41.1210.8911.4816.81
Operating Income-4.96-6.66-11.95-14.96-14.20-12.4331.37-3.90-3.51-13.70
Net Income-4.63-6.56-11.91-14.85-14.15-12.3931.54-3.45-2.61-12.02
Shares Outstanding17.4110.686.546.526.486.476.436.396.316.09
Earnings Per Share-0.27-0.61-1.82-2.28-2.17-1.894.90-0.56-0.42-1.96
Dividend Per Share-------5.25-14.00
Operating Cash Flow-2.51-4.77-8.24-12.23-9.05-9.55-6.95-7.17-0.26-0.14
Capital Expenditures-0.02---0.08-0.20-0.08----
Free Cash Flow-2.53-4.77-8.24-12.31-9.25-9.63-6.95-7.17-0.26-0.14
Cash & Equivalents23.0819.8110.4818.7131.3040.5949.8456.2598.1391.23
Total Debt0.09---------
Net Cash / Debt22.9919.8110.4818.7131.3040.5949.8456.2598.1391.23
Book Value22.1019.639.7018.6429.3740.0648.3013.1444.3932.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cassava Sciences, Inc.
Country United States
Employees 9
CEO Remi Barbier

Stock Information

Ticker Symbol SAVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SAVA


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.